Výsledky vyhledávání - "Carlos M. DeCastro"

Data from A Genomic Approach to Improve Prognosis and Predict Therapeutic Response in Chronic Lymphocytic Leukemia

Autor: Joseph R. Nevins, Anil Potti, Carlos M. Decastro, Louis F. Diehl, Jon P. Gockerman, Joseph O. Moore, Ning Jiang, Youwei Chen, Karen M. Bond, Alicia D. Volkheimer, Barbara K. Goodman, William T. Barry, J. Brice Weinberg, Daphne R. Friedman

Purpose: Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by a variable clinical course. Several parameters have prognostic capabilities but are associated with altered response to therapy in only a small subset of patients.Exp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15345022c81aaa9bee5c247199a481be
https://doi.org/10.1158/1078-0432.c.6517326.v1

Zobrazit plný text záznamu

Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia

Autor: Anand S. Lagoo, Arati V. Rao, Zhiguo Li, Louis F. Diehl, Tod A. Morris, David A. Rizzieri, Joseph O. Moore, Jon P. Gockerman, Carlos M. DeCastro

Publikováno v: Leukemia Research. 37:28-31

The decision to re-induce patients with acute myeloid leukemia (AML) based on results of the day 14 bone marrow (BM) biopsy is variable and lacks evidence based data. The aim of our review was to evaluate the accuracy of a day 14 BM biopsy in determi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::105dffc363b5dce850f9faa44ff7ffb6
https://doi.org/10.1016/j.leukres.2012.09.016

Zobrazit plný text záznamu

Phase I study of dose dense induction and consolidation with gemtuzumab ozogamicin and high dose cytarabine in older adults with AML

Autor: Arati V. Rao, Anand S. Lagoo, David A. Rizzieri, Jon P. Gockerman, Louis F. Diehl, Joseph O. Moore, Carlos M. DeCastro

Publikováno v: Journal of Geriatric Oncology. 3:220-227

Objective Older adults with acute myeloid leukemia (AML) tend to have worse complete remission (CR) rates and overall survival compared to their younger counterparts. At least one reason for this is increased expression of the multidrug resistance ge

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2c475f7a94b39ecc44ff3b278dc6226d
https://doi.org/10.1016/j.jgo.2012.02.002

Zobrazit plný text záznamu

Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia

Autor: Mark C. Lanasa, Catherine Rehder, Michael B. Datto, Jon P. Gockerman, Zhiguo Li, Louis F. Diehl, Harry Cook, Joseph O. Moore, David A. Rizzieri, Carlos M. DeCastro, J. Brice Weinberg, F Joseph Daugherty, Karen M. Matta, Daphne R. Friedman, Patricia H. Davis

Publikováno v: Leukemia & Lymphoma. 53:218-224

Patients with chronic lymphocytic leukemia (CLL) with deletion or mutation of TP53 have exceedingly poor clinical outcomes. Cenersen, an oligonucleotide targeting TP53, has been shown to abrogate the activity of TP53 gain-of-function mutants and to i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae8c3ea5bf9699ee959642bedb59e2ff
https://doi.org/10.3109/10428194.2011.610012

Zobrazit plný text záznamu

A Genomic Approach to Improve Prognosis and Predict Therapeutic Response in Chronic Lymphocytic Leukemia

Autor: Daphne R. Friedman, Karen M. Bond, Youwei Chen, Ning Jiang, Carlos M. DeCastro, Anil Potti, Alicia D. Volkheimer, Joseph O. Moore, Barbara K. Goodman, Joseph R. Nevins, J. Brice Weinberg, Jon P. Gockerman, Louis F. Diehl, William T. Barry

Publikováno v: Clinical Cancer Research. 15:6947-6955

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa911b45b514189ba2df13ab3a5f3f15
https://doi.org/10.1158/1078-0432.ccr-09-1132

Zobrazit plný text záznamu

Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia

Autor: Bercedis L. Peterson, Islam R. Younis, David J. Adams, Arati V. Rao, Ivan Spasojevic, David A. Rizzieri, Joseph O. Moore, John P. Gockerman, William P. Petros, Gregory J. Sand, Carlos M. DeCastro

Publikováno v: Leukemia & Lymphoma. 49:1523-1529

Our aim was to estimate the duration of maximum tolerated dose (MTD) duration for gemcitabine given as a continuous infusion in combination with fludarabine and mitoxantrone and to evaluate potential pharmacokinetic (PK) interactions in 17 patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69ac1907993df3fbfb20c33a0f997dcf
https://doi.org/10.1080/10428190802210700

Zobrazit plný text záznamu

Plný text ve formátu HTML

Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma

Autor: Carlos M. DeCastro, Gwynn D. Long, Elizabeth Anderson, Donna Adams, Cristina Gasparetto, Joseph O. Moore, Donna Niedzwiecki, Nelson J. Chao, Jon P. Gockerman, James J. Vredenburgh, Tracy Foster, Dean S. McGaughey, David A. Rizzieri, Bonnie Toaso, Gregory J. Sand

Publikováno v: Cancer. 100:2408-2414

BACKGROUND Many patients with recurrent, intermediate or high-grade non-Hodgkin lymphoma (NHL) may not respond to or are not candidates for aggressive salvage chemotherapy. Effective, less toxic regimens are needed. Although high-dose taxanes have no

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6abd9f3bdbb36cdf83ac3027cf05f371
https://doi.org/10.1002/cncr.20245

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání